Zavicefta is given by intravenous infusion to treat complicated intra-abdominal infections, complicated urinary tract infections including pyelonephritis, and hospital-acquired pneumonia including ventilator-associated pneumonia. It can also be used in the treatment of aerobic Gram-negative infections in patients with limited treatment options.
Ceftazidime is an established third-generation cephalosporin. The addition of avibactam protects ceftazidime against degradation by bacterial β-lactamases.
According to the manufacturer, Zavicefta has been developed in response to the urgent need for new antibiotics to treat serious infections that are becoming increasingly resistant, such as multi-drug resistant Pseudomonas aeruginosa, carbapenem-resistant Gram-negative pathogens, and ESBL-producing Enterobacteriaceae.